Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276223 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
A Phase 2 study, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 722
- Enrollment target
NCT01276223: Completed Phase 2 study, sponsored by Alcon Research.
NCT01276223 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 722 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01276223, a Phase 2 study, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 722 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
Primary Outcome
A Visual Analog Scale (VAS) was used by the subject to assess ocular discomfort, both frequency and severity, at baseline (pre-treatment) and weekly thereafter for 4 additional weeks. Each scale was 100 millimeters (mm) in length. The VAS score was calculated by measuring the length in mm from the start of the line to the intersection point of the vertical mark made by the subject. The Global Ocular Discomfort Score is a composite of the two VAS scores, ranging from 0 (very mildly) to 100 (very
Interventions
- DRUG Difluprednate 0.05% ophthalmic emulsion
- OTHER Difluprednate vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT01276223 record still lists
NCT01276223 is an interventional study that assigns participants to a tested intervention. The registered 722 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (443% higher).
The record links to 0 conditions, and to 2 interventions - of which Difluprednate 0.05% ophthalmic emulsion is the first listed.
NCT01276223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01276223 about?
NCT01276223 is a clinical study titled "Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients". The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
What is the current status of trial NCT01276223?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 722 participants. The study started on 2011-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01276223?
The interventions under investigation include: Difluprednate 0.05% ophthalmic emulsion (DRUG), Difluprednate vehicle (OTHER).
Who is sponsoring clinical trial NCT01276223?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01276223's enrollment target sits among peer trials
722 45th of 2000 higher than 1,956 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06116149 · 722 participants · NA
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia